Ignite Creation Date:
2025-12-25 @ 3:22 AM
Ignite Modification Date:
2025-12-26 @ 2:00 AM
Study NCT ID:
NCT06967805
Status:
RECRUITING
Last Update Posted:
2025-12-02
First Post:
2025-04-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D054990', 'term': 'Idiopathic Pulmonary Fibrosis'}, {'id': 'D005355', 'term': 'Fibrosis'}], 'ancestors': [{'id': 'D011658', 'term': 'Pulmonary Fibrosis'}, {'id': 'D017563', 'term': 'Lung Diseases, Interstitial'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 164}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-05-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2027-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-24', 'studyFirstSubmitDate': '2025-04-14', 'studyFirstSubmitQcDate': '2025-05-08', 'lastUpdatePostDateStruct': {'date': '2025-12-02', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-05-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'To assess the development of antidrug antibodies (ADA) against MTX-463', 'timeFrame': '28 Weeks', 'description': 'Samples will be collected from baseline until Week 28 to assess the rate at which antibodies develop to the study drug'}, {'measure': 'To assess the effect of MTX-463 on the change from Baseline in FVC in participants on concomitant nintedanib or pirfenidone', 'timeFrame': '24 Weeks', 'description': 'The change from baseline to week 24 in the mean FVC (in ML) will be measured in each group in the subset of participants who enter the study on background IPF medications, pirfenidone or nintedanib'}, {'measure': 'To assess the effect of MTX-463 on the change from Baseline in FVC in participants not on concomitant nintedanib or pirfenidone', 'timeFrame': '24 Weeks', 'description': 'The change from baseline to week 24 in the mean FVC (in ML) will be measured in each group in the subset of participants who enter the study not on any background IPF medications, pirfenidone or nintedanib'}, {'measure': 'To assess the effect of MTX-463 on the change from Baseline in the Living with Pulmonary Fibrosis (L-PF) Questionnaire total score', 'timeFrame': '24 Weeks', 'description': 'Change from Baseline to Week 24 in L-PF total score. The L-PF is scored on a scale of 0-100, with higher numbers indicating greater impairment.'}, {'measure': 'To assess whether serum WNT-inducible signaling pathway protein 1 (WISP1) levels at Screening predict improved outcomes with MTX-463 treatment', 'timeFrame': '24 Weeks', 'description': '* Change from Baseline to Week 24 in total WISP1 levels\n* Change from Baseline to Week 24 in free WISP1 levels\n* Change from Baseline to Week 24 in FVC by free and total WISP1 screening quartiles'}, {'measure': 'To assess the effect of MTX-463 on the change from Baseline in percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO)', 'timeFrame': '24 Weeks', 'description': 'Change from Baseline to Week 24 in percent predicted DLCO'}, {'measure': 'To evaluate the time to disease progression as determined by change in FVC, IPF-related changes, or death', 'timeFrame': '28 Weeks', 'description': 'Time to disease progression with progression being defined as ≥10% decline in FVC from Baseline, IPF related hospitalization, or death'}, {'measure': 'To assess the effect of MTX-463 on Pro-C3', 'timeFrame': '24 Weeks', 'description': 'The mean change from baseline to week 24 in the level of ProC3, a biomarker of IPF, in the serum will be measured in each group'}, {'measure': 'To assess the effect of MTX-463 on interleukin-6', 'timeFrame': '24 Weeks', 'description': 'The mean change from baseline to week 24 in the level of interleukin-6 (IL-6), a biomarker of IP, in the serum will be measured in each group'}], 'primaryOutcomes': [{'measure': 'To assess the effect of MTX-463 on the change from Baseline in forced vital capacity (FVC)', 'timeFrame': '24 Weeks', 'description': 'Change from Baseline to Week 24 in Forced Vital Capacity (FVC)'}], 'secondaryOutcomes': [{'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment emergent adverse events', 'timeFrame': '28 Weeks', 'description': 'Incidence of treatment-emergent adverse events (TEAEs) from Baseline until Week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment related adverse events', 'timeFrame': '28 Weeks', 'description': 'Incidence of treatment related adverse events from baseline until Week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of serious treatment emergent adverse events', 'timeFrame': '28 Weeks', 'description': 'Incidence of serious treatment emergent adverse events from baseline until Week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of severe treatment emergent adverse events', 'timeFrame': '28 Weeks', 'description': 'Incidence of severe treatment emergent adverse events from Baseline until week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment emergent abnormalities on clinical laboratory tests', 'timeFrame': '28 Weeks', 'description': 'Incidence of treatment emergent abnormalities on clinical laboratory tests from baseline until Week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of abnormal findings on physical exam', 'timeFrame': '28 Weeks', 'description': 'Incidence of abnormal findings on physical exam from baseline until Week 28 in each group'}, {'measure': 'To assess the safety and tolerability of MTX-463 in participants with IPF, as measured by incidence of treatment discontinuations', 'timeFrame': '28 Weeks', 'description': 'Incidence of treatment discontinuations from baseline until Week 28 in each group'}, {'measure': 'To assess the effect of MTX-463 on the change from Baseline in the percent predicted FCV (FVCpp)', 'timeFrame': '24 Weeks', 'description': 'Change from Baseline to Week 24 in the percent predicted FVC (FVCpp)'}, {'measure': 'To collect sparse pharmacokinetics (PK) of MTX-463 in participants with IPF', 'timeFrame': '24 Weeks', 'description': 'Samples will be collected from baseline until Week 24 to assess the trough serum concentrations of the study drug'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['MTX-463-I201', 'MTX-463', 'IPF', 'Idiopathic Pulmonary Fibrosis', 'Adult', 'Fibrosis', 'Monoclonal Antibody', 'MAB', 'FVC', 'WISPer'], 'conditions': ['Idiopathic Pulmonary Fibrosis']}, 'descriptionModule': {'briefSummary': 'A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)', 'detailedDescription': "Participants with IPF who meet the study's inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to receive MTX-463 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved IPF therapies, pifenidone or nintedanib, is permitted, and it is expected that about half the study population will be on one of those medications. Participants randomized to the MTX-463 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, 4 weeks after the final infusion; and a final Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. Assessments of FVC will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. L-PF assessments will be performed at Baseline and Week 24. Participants will have blood drawn for safety assessment and to assess WISP1 levels at Baseline and every 4 weeks throughout the study. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-463."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants with IPF of any gender ≥ 40 years of age at time of signing the informed consent.\n* Able to understand the study and provide signed, written informed consent.\n* Able to read and understand the language of the informed consent and other trial-related materials.\n* Meet the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) 2019 criteria for the diagnosis of IPF; Diagnosed with IPF within 7 years of screening.\n* If a participant is on treatment with pirfenidone or nintedanib, the dose of the medication must be stable for ≥ 90 days prior to Screening with plans to maintain the same dose throughout the study treatment period. Use of both agents together is not permitted.\n* If a participant was on treatment with nintedanib or pirfenidone, and the agent has been discontinued, this must have occurred ≥ 30 days prior to Screening. At Screening, there must also be no plan to start either of these medications for the duration of the study.\n* FVC of ≥ 45 percent predicted (pp) at screening.\n* DLCO of ≥ 25pp at screening.\n* Willing and able to complete all protocol required study visits and procedures.\n* All participants of childbearing potential must have a negative serum pregnancy test at Screening.\n* Participants with reproductive potential must agree to use and follow medically approved contraceptive precautions during the study\n\nExclusion Criteria:\n\n* Acute exacerbation of IPF within 6 months of Screening or during the Screening Period.\n* Forced expiratory volume in 1 second (FEV1)/FVC ratio of \\<0.7 at Screening.\n* Requirement for continuous supplemental oxygen. Intermittent supplemental oxygen use (e.g., during exercise or sleep) is permitted.\n* Expected to receive a lung transplant within the study duration.\n* Current active bacterial infection or use of antibiotics for suspected lung infection in the 30 days prior to Screening.\n* Planned surgery within the study duration.\n* Clinically significant pulmonary hypertension.\n* Use of immunosuppressive therapy (excluding corticosteroids). If previously on such agents, they should have been discontinued for at least 5 half-lives or 90 days, whichever is longer, prior to Screening.\n* Use of systemic corticosteroids (prednisone or equivalent) at a dose ≥ 10 mg once daily within 30 days of Screening.\n* Currently smoking or vaping.\n* Current known malignancy, or history of cancer, or lymphoproliferative disorder other than non-melanomatous skin cancers, within 2 years of Screening.\n* Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).\n* Currently pregnant, breast feeding, or planning to conceive for the length of the study.\n* History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 2 years of Screening.\n* Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2× upper limit of normal (ULN) at Screening.\n* Any other concurrent active medical condition determined by the Investigator to interfere with participant's ability to complete the trial.\n* Known allergy to MTX-463 or any of its excipients.\n* Any prior use of MTX-463 or other therapy targeting WISP1.\n* Any other concurrent experimental agent or an active part of any other clinical trial, unless they have stopped taking the investigational product at least 5 half-lives or 30 days before Screening, whichever is longer."}, 'identificationModule': {'nctId': 'NCT06967805', 'briefTitle': 'WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Mediar Therapeutics'}, 'officialTitle': 'A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)', 'orgStudyIdInfo': {'id': 'MTX-463-I201'}, 'secondaryIdInfos': [{'id': '2025-521278-32', 'type': 'EUDRACT_NUMBER'}, {'id': 'WISPer', 'type': 'OTHER', 'domain': 'Mediar Therapeutics'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MTX-463', 'description': 'MTX-463', 'interventionNames': ['Biological: MTX-463']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'MTX-463', 'type': 'BIOLOGICAL', 'description': 'MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.', 'armGroupLabels': ['MTX-463']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Placebo', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Birmingham, AL', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85032', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Phoenix, AZ', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Newport Beach, CA', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '92203', 'city': 'Palm Springs', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Palm Springs, CA', 'geoPoint': {'lat': 33.8303, 'lon': -116.54529}}, {'zip': '33470', 'city': 'Loxahatchee Groves', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Loxahatchee, FL', 'geoPoint': {'lat': 26.68368, 'lon': -80.27977}}, {'zip': '61822', 'city': 'Champaign', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Champaign, IL', 'geoPoint': {'lat': 40.11642, 'lon': -88.24338}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Kansas City, KS', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '71103', 'city': 'Shreveport', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Shreveport, LA', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '21224', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Baltimore, MD', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Detroit, MI', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in New York, NY', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27403', 'city': 'Greensboro', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Greensboro, NC', 'geoPoint': {'lat': 36.07264, 'lon': -79.79198}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Oklahoma City, OK', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '75204', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Dallas, TX', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '4120', 'city': 'Greenslopes', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Greenslopes, Australia', 'geoPoint': {'lat': -27.50815, 'lon': 153.04951}}, {'zip': '3004', 'city': 'Melbourne', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Melbourne, Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '6056', 'city': 'Midland', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Midland, Australia', 'geoPoint': {'lat': -31.88909, 'lon': 116.0107}}, {'zip': '2145', 'city': 'Westmead', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Westmead, Australia', 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'zip': 'L1S 2J5', 'city': 'Ajax', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Ajax, ON', 'geoPoint': {'lat': 43.85012, 'lon': -79.03288}}, {'zip': 'G8T 7A1', 'city': 'Trois-Rivières', 'state': 'Quebec', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer site in Trois-Rivières, Quebec', 'geoPoint': {'lat': 46.34515, 'lon': -72.5477}}, {'zip': 'B15 2GW', 'city': 'Birmingham', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Birmingham, UK', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'CB2 0BB', 'city': 'Cambridge', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Cambridge, UK', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'EH16 4SA', 'city': 'Edinburgh', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'WISPer Contact', 'role': 'CONTACT', 'email': 'wisper@mediartx.com', 'phone': '617-468-1770'}], 'facility': 'WISPer Site in Edinburgh, UK', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}], 'centralContacts': [{'name': 'Jeffrey Bornstein, MD', 'role': 'CONTACT', 'email': 'Jeffrey@mediartx.com', 'phone': '(617) 936-0960', 'phoneExt': '803'}, {'name': 'Katherine Palu', 'role': 'CONTACT', 'email': 'katherine@mediartx.com', 'phone': '(617) 936-0960', 'phoneExt': '810'}], 'overallOfficials': [{'name': 'Todd Astor, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Mediar Therapeutics'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mediar Therapeutics', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}